

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/713,790		ATTY. DOCKET NO.: B0801.70255US01	
				FILING DATE: November 12, 2003		CONFIRMATION NO.: 5867	
				APPLICANT: Pier et al.			
				GROUP ART UNIT: 1645		EXAMINER: Sarvamangala J. N. Devi	
Sheet	1	of	2				

U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
		4,465,776		Pier et al.	08-14-1984
		6,924,360		Green et al.	08-02-2005

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
		WO	03/085093	A2	Human Genome Sciences, Inc.	10-16-2003	

OTHER ART – NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		GenBank Submission;NIH/BCBI; Accession No. DQ231549; Kelly-Quintos et al; Printed May 9, 2006.	
		GenBank Submission;NIH/BCBI; Accession No. DQ231550; Kelly-Quintos et al; Printed May 9, 2006.	
		GenBank Submission;NIH/BCBI; Accession No. DQ231551; Kelly-Quintos et al; Printed May 9, 2006.	
		GenBank Submission;NIH/BCBI; Accession No. DQ231552; Kelly-Quintos et al; Printed May 9, 2006.	
		GenBank Submission;NIH/BCBI; Accession No. DQ231553; Kelly-Quintos et al; Printed May 9, 2006.	
		GenBank Submission;NIH/BCBI; Accession No. DQ231554; Kelly-Quintos et al; Printed May 9, 2006.	
		GenBank Submission;NIH/BCBI; Accession No. AF086783; Cramton et al; BCT October 1, 1999.	
		GenBank Submission;NIH/BCBI; Accession No. AAZ87998; Pier et al; May 31, 2000.	
		New York Times, Editorial, Another Very Scary Germ. November 20, 2007. Available at http://www.nytimes.com/2007/11/20/opinion/20tue2.html?_r=2&oref=slogin&pagewanted . Last accessed April 30, 2010. 2 pages.	
		CERCA et al., Comparative antibody-mediated phagocytosis of Staphylococcus epidermidis cells grown in a biofilm or in the planktonic state. Infect Immun. 2006 Aug;74(8):4849-55.	
		CERCA et al., Influence of batch or fed-batch growth on Staphylococcus epidermidis biofilm formation. Lett Appl Microbiol. 2004;39(5):420-4.	
		CERCA et al., Molecular basis for preferential protective efficacy of antibodies directed to the poorly acetylated form of staphylococcal poly-N-acetyl-beta-(1-6)-glucosamine. Infect Immun. 2007 Jul;75(7):3406-13. Epub 2007 Apr 30.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/713,790	ATTY. DOCKET NO.: B0801.70255US01
				FILING DATE: November 12, 2003	CONFIRMATION NO.: 5867
				APPLICANT: Pier et al.	
				GROUP ART UNIT: 1645	EXAMINER: Sarvamangala J. N. Devi
Sheet	2	of	2		

		CERCA et al., Protection against Escherichia coli infection by antibody to the Staphylococcus aureus poly-N-acetylglucosamine surface polysaccharide. Proc Natl Acad Sci U S A. 2007 May 1;104(18):7528-33. Epub 2007 Apr 19.	
		DE PASCALIS et al., Grafting of "abbreviated" complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody. J Immunol. 2002 Sep 15;169(6):3076-84.	
		HUANG et al., Risk of methicillin-resistant Staphylococcus aureus infection after previous infection or colonization. Clin Infect Dis. 2003 Feb 1;36(3):281-5. Epub 2003 Jan 17.	
		KELLY-QUINTOS et al., The role of epitope specificity in the human opsonic antibody response to the staphylococcal surface polysaccharide poly N-acetyl glucosamine. J Infect Dis. 2005 Dec 1;192(11):2012-9. Epub 2005 Nov 1.	
		KLEVENS et al., Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA. 2007 Oct 17;298(15):1763-71.	
		KROPEC et al., Poly-N-acetylglucosamine production in Staphylococcus aureus is essential for virulence in murine models of systemic infection. Infect Immun. 2005 Oct;73(10):6868-76.	
		KUEHNERT et al., Methicillin-resistant-Staphylococcus aureus hospitalizations, United States. Emerg Infect Dis. 2005 Jun;11(6):868-72. Erratum in: Emerg Infect Dis. 2006 Sep;12(9):1472.	
		MACCALLUM et al., Antibody-antigen interactions: contact analysis and binding site topography. J Mol Biol. 1996 Oct 11;262(5):732-45.	
		MAIRA-LITRAN et al., Biologic properties and vaccine potential of the staphylococcal poly-N-acetyl glucosamine surface polysaccharide. Vaccine. 2004 Feb 17;22(7):872-9. Review.	
		MIKAYAMA et al., Molecular cloning and functional expression of a cDNA encoding glycosylation-inhibiting factor. Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10056-60.	
		SACK, Deadly Bacteria Found to Be More Common. New York Times. October 17, 2007. Available at http://www.nytimes.com/2007/10/17/health/17infect.html?pagewanted=prin . Last accessed April 30, 2010. 3 pages.	
		ZELLER et al., JAMA patient page. MRSA infections. JAMA. 2007 Oct 17;298(15):1826.	

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.